Contents of this article
The cardiovascular system is tightly regulated by peptides that control vascular tone, fluid balance, cardiac contractility, and metabolic health. From the natriuretic peptides secreted by the heart to innovative GLP-1-based drugs that lower cardiovascular risk, peptides act as key regulators and promising therapeutic tools. Modern research continues to expand their role, linking peptide biology not only to blood pressure and heart failure but also to obesity-related cardiovascular disease prevention.
Peptides in cardiovascular physiology
Peptides serve as hormones, neurotransmitters, and local paracrine factors within the cardiovascular system. They regulate vascular smooth muscle tone, myocardial remodeling, and renal sodium handling, ensuring stable blood pressure and circulation.
Natriuretic Peptides
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are released from the heart in response to atrial or ventricular stretch. They promote vasodilation, natriuresis, and diuresis, reducing preload and afterload. Clinically, BNP and its precursor NT-proBNP are vital biomarkers for diagnosing and monitoring heart failure.
Endothelin system
The endothelin peptides (ET-1, ET-2, ET-3) are potent vasoconstrictors produced by endothelial cells. While crucial for basal vascular tone, excessive endothelin activity contributes to systemic hypertension and pulmonary arterial hypertension (PAH). Endothelin receptor antagonists (for example, Bosentan, Ambrisentan, Macitentan) are approved therapies that improve symptoms and outcomes in PAH.
Renin-Angiotensin-Aldosterone axis
The angiotensin peptides (Ang II, Ang 1-7) are central regulators of cardiovascular function. Angiotensin II raises blood pressure via vasoconstriction and aldosterone release, while Ang 1-7 often counters these effects through vasodilation and antifibrotic actions. Modulation of this peptide axis (ACE inhibitors, ARBs, ARNIs) remains foundational in treating hypertension and heart failure.
Peptides and cardiovascular disease biomarkers
Measurement of circulating peptides is a cornerstone of cardiovascular diagnostics.
- BNP and NT-proBNP levels correlate with ventricular dysfunction and prognosis in heart failure.
- Cardiac troponins are peptide/protein fragments central to diagnosing myocardial infarction.
- Copeptin (a stable peptide derived from the vasopressin precursor) is an actively studied adjunct biomarker for early detection and risk stratification in acute myocardial injury.
Peptide therapeutics in cardiovascular medicine
GLP-1 receptor agonists
Originally developed for diabetes, GLP-1 analogs such as Semaglutide have been shown in large randomized trials to reduce cardiovascular events in people with overweight/obesity and/or established cardiovascular disease. Semaglutide also improved symptoms and exercise capacity in trials of HFpEF patients with obesity.
Dual and triple agonists
Tirzepatide (GIP/GLP-1 dual agonist) and Retatrutide (GIP/GLP-1/glucagon triple agonist) demonstrated large weight-loss and favorable cardiometabolic effects in phase 2/3 trials, and are being investigated for downstream cardiovascular risk reduction as obesity and metabolic dysfunction are major drivers of cardiovascular disease.
Endothelin receptor antagonists
In pulmonary arterial hypertension, endothelin receptor antagonists such as Bosentan and Macitentan improve exercise capacity and delay clinical worsening by blocking ET-1-mediated vasoconstriction and remodeling.
Natriuretic Peptide-based therapies
Nesiritide, a recombinant human BNP, was explored for acute decompensated heart failure with mixed results; newer designer natriuretic peptides and delivery strategies remain under investigation to harness beneficial hemodynamic and renal effects with improved tolerability.
Neprilysin inhibition
The angiotensin receptor-neprilysin inhibitor (Sacubitril/Valsartan, an ARNI) increases natriuretic peptide levels by inhibiting their breakdown and improved outcomes compared with ACE inhibitors in HFrEF (PARADIGM-HF). ARNIs are now part of guideline-recommended HFrEF therapy.
Advances in Peptide delivery for the cardiovascular system
Advances in cardiovascular peptide delivery are focusing on oral formulations, long-acting depot systems, and engineered carriers that enhance stability, prolong half-life, and enable targeted cardiac or vascular tissue uptake, improving both efficacy and patient adherence.
Safety and access considerations
Peptide therapies are generally well tolerated, but hypotension, gastrointestinal side effects, renal effects, and cost are important issues. For GLP-1-based drugs, gradual dose titration reduces GI adverse effects; for ARNI, clinicians monitor blood pressure and renal function. Access and reimbursement vary by country and health system, which affects equitable use.
Ongoing areas of research include:
- Oral formulations of peptide drugs for easier administration.
- Biased ligands that selectively trigger beneficial intracellular signaling downstream of peptide receptors.
- Peptide mimetics and small molecules that reproduce peptide activity with better stability and oral bioavailability.
- Gene and mRNA therapies to increase local endogenous peptide production in cardiac or vascular tissue.
Peptides are fundamental to cardiovascular homeostasis; regulating vascular tone, cardiac performance, and fluid balance and are now central to modern therapeutic innovation. From natriuretic peptides guiding heart failure management to GLP-1-based agents improving cardiovascular outcomes in obesity, peptide biology has rapidly translated into real-world clinical impact. Emerging multi-agonists, biased ligands, and gene-based peptide therapies suggest that cardiometabolic disease can be targeted more precisely than ever before. As access expands and long-term safety continues to be monitored, peptides are positioned to play an even greater role in reducing the global burden of cardiovascular disease, shifting care from reactive treatment to preventive, mechanism-driven medicine.
Research sources:
Natriuretic peptide pathways in heart failure: further therapeutic possibilities
S Jeson Sangaralingham, Michaela Kuhn, Valentina Cannone, Horng H Chen, and John C Burnett Jr. Published in Cardiovascular Research 2022 | DOI: 10.1093/cvr/cvac125
Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy
Frederik C. Enevoldsen, Jayashree Sahana, Markus Wehland, Daniela Grimm, Manfred Infanger, and Marcus Krüger. Published in MDPI Journal of Clinical Medicine 2020 | DOI: 10.3390/jcm9030824
Paul K. Whelton, MB, MD, MSc, FAHA, Robert M. Carey, MD, FAHA, Wilbert S. Aronow, MD, FACC, FAHA, Donald E. Casey, Jr, MD, MPH, MBA, FAHA, Karen J. Collins, MBA, Cheryl Dennison Himmelfarb, RN, ANP, PhD, FAHA, Sondra M. DePalma, MHS, PA-C, CLS, AACC, Samuel Gidding, MD, FAHA, Kenneth A. Jamerson, MD, Daniel W. Jones, MD, FAHA, Eric J. MacLaughlin, PharmD, Paul Muntner, PhD, FAHA, Bruce Ovbiagele, MD, MSc, MAS, MBA, FAHA, Sidney C. Smith, Jr, MD, MACC, FAHA, Crystal C. Spencer, JD, Randall S. Stafford, MD, PhD, Sandra J. Taler, MD, FAHA, Randal J. Thomas, MD, MS, FACC, FAHA, Kim A. Williams, Sr, MD, MACC, FAHA, Jeff D. Williamson, MD, MHS, and Jackson T. Wright, Jr, MD, PhD, FAHA. Published in AHA in Hypertension 2017 | DOI: 10.1161/HYP.0000000000000065
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel, John G F Cleland, Andrew J S Coats, Maria G Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W Hoes, Tiny Jaarsma, Ewa A Jankowska, Mitja Lainscak, Carolyn S P Lam, Alexander R Lyon, John J V McMurray, Alexandre Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe M C Rosano, Frank Ruschitzka, and Anne Kathrine Skibelund. Published in Oxford Academic in European Heart Journal 2021 | DOI: 10.1093/eurheartj/ehab368
Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases
Danni Mu, Jin Cheng, Ling Qiu, and Xinqi Cheng. Published in Frontiers in Cardiovascular Medicine 2022 | DOI: 10.3389/fcvm.2022.901990
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, M.D., Kirstine Brown-Frandsen, M.D., Helen M. Colhoun, M.D., John Deanfield, M.D., Scott S. Emerson, M.D., Ph.D., Sille Esbjerg, M.Sc., Søren Hardt-Lindberg, M.D., Ph.D., G. Kees Hovingh, M.D., Ph.D., Steven E. Kahn, M.B., Ch.B., Robert F. Kushner, M.D., Ildiko Lingvay, M.D., M.P.H., Tugce K. Oral, M.D., Marie M. Michelsen, M.D., Ph.D., Jorge Plutzky, M.D., Christoffer W. Tornøe, Ph.D., and Donna H. Ryan, M.D., for the SELECT Trial Investigators. Published in The New England Journal of Medicine 2023 | DOI: 10.1056/NEJMoa2307563
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, M.D., Breno Alves, M.D., Arihiro Kiyosue, M.D., Ph.D., Shuyu Zhang, M.S., Bing Liu, Ph.D., Mathijs C. Bunck, M.D., Ph.D., and Adam Stefanski, M.D., Ph.D., for the SURMOUNT-1 Investigators. Published in The New England Journal of Medicine 2022 | DOI: 10.1056/NEJMoa2206038
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure